All In Biotech

Drug Trial Radar · NCT04899115

VE303 for Treatment of Hepatic Encephalopathy (HE)

A Randomized Controlled Trial of VE303 to Treat Hepatic Encephalopathy

Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

19

Actual

Start

Aug 6, 2021

Primary completion

Apr 10, 2023

Study completion Aug 30, 2023

Sponsor

Lead sponsor
Patricia BloomAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Vedanta Biosciences, Inc.; American College of Gastroenterology; American Association for the Study of Liver Diseases
First posted
May 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is studying the use of a new drug to learn about its safety and efficacy as a treatment for hepatic encephalopathy. Eligible participants will be enrolled and given oral antibiotics followed by 14 days of the study drug (placebo vs.VE303). There will be visits as well as other procedures to collect blood and stool samples, and have tests of your cognition (thinking) for this research study. The hypothesis is that VE303 will safely and effectively improve cognitive function in patients with a history of overt hepatic encephalopathy.

Conditions

  • Cirrhosis
  • Hepatic Encephalopathy

Interventions

  • PlaceboDrug

    Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.

  • VE303Drug

    Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days. The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules.

  • oral vancomycinDrug

    All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Serious Adverse Events up to Week 6Time frame: Week 6
  2. Change in Psychometric Hepatic Encephalopathy Score (PHES) as a Measure of Cognitive Function From Pre-vancomycin to Week 6Time frame: baseline (pre-vancomycin), Week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.